MediPharm Labs, VIVO Cannabis to Merge

International sales are expected to grow under the combination.

Canadian marijuana companies MediPharm (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) and VIVO Cannabis Inc. (TSX: VIVO) (OTCQB: VVCIF) are on track to merge next year in an all-equity deal, as long as shareholders and regulators approve.

The newly combined company is projected to bring in $36.5 million in revenue per year and become profitable by the second half of 2024, according to a press release.

The new company, which will keep the name MediPharm Labs, will have an international and medical focus instead of a domestic recreational plan, MediPharm CEO David Pidduck said.

“Both VIVO and MediPharm saw the future in cannabis wellness products and in pharmaceutical drugs containing cannabis,” Pidduck said in the release. “Through this business combination, we have identified the potential for millions in cost and revenue synergies.”

VIVO brings with it connections in the German and Australian medical cannabis markets, and MediPharm is already an established cannabis concentrate company with an international footprint. International sales, under the company’s projections, should account for $14.6 million of the $36.5 million in forecasted revenues.

Following the closing of the merger, existing MediPharm shareholders will have between 65%-79% of the combined company, while VIVO shareholders will own between 21%-35%.

The merger may not be MediPharms’ last. The company has been “actively pursuing M&A opportunities in the industry since June,” Pidduck said and hinted the company has more expansion plans in the works.

John Schroyer


Leave a Reply

Your email address will not be published. Required fields are marked *

Choose Your News

Subscribe to the Green Market Report newsletter that gives you original content delivered straight to your inbox.

 Subscribe

By continuing I agree to your Privacy Policy and consent to receive relevant newsletters and other email communications on events, editorial features, and special partner offers from Green Market Report. I can unsubscribe or change my email preferences at any time.


About Us

The Green Market Report focuses on the financial news of the rapidly growing cannabis industry. Our target approach filters out the daily noise and does a deep dive into the financial, business and economic side of the cannabis industry. Our team is cultivating the industry’s critical news into one source and providing open source insights and data analysis


READ MORE



Recent Tweets

@GreenMarketRpt – 3 hours

FDA Says CBD Still Can’t Be Dietary Supplement

@GreenMarketRpt – 7 hours

Mind Cure Continues Its Winding Down Process

Back to Top

Choose Your News

Subscribe to the Green Market Report newsletter that gives you original content delivered straight to your inbox.

 Subscribe

By continuing I agree to your Privacy Policy and consent to receive relevant newsletters and other email communications on events, editorial features, and special partner offers from Green Market Report. I can unsubscribe or change my email preferences at any time.